Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis Pharmaceuticals |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00439738 |
The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure [MSSBP] >150 mmHg) patients.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: HCTZ + Amlodipine Drug: Valsartan/HCTZ |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 16-Week Double-Blind, Randomized, Multicenter, Force-Titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients |
Enrollment: | 412 |
Study Start Date: | December 2006 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
valsartan/HCTZ: Experimental |
Drug: Valsartan/HCTZ
|
HCTZ +Amlodipine: Active Comparator |
Drug: HCTZ + Amlodipine
|
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
United States, Alabama | |
Terence T. Hart, MD | |
Muscle Shoals, Alabama, United States, 35662 | |
United States, California | |
Westlake Medical Research | |
Westlake Village, California, United States, 91361 | |
United States, Oklahoma | |
Oklahoma Cardiovascular & Hypertension | |
Oklahoma City, Oklahoma, United States, 73132 | |
United States, Texas | |
Northeast Tarrant Internal Medicine Assoc | |
Euless, Texas, United States, 76040 | |
United States, Washington | |
Frandsen Family Medicine | |
Port Orchard, Washington, United States, 98366 |
Study Chair: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals ( External Affairs ) |
Study ID Numbers: | CVAH631BUS06 |
Study First Received: | February 23, 2007 |
Results First Received: | November 5, 2008 |
Last Updated: | February 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00439738 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Obesity, hypertension, valsartan/hydrochlorothiazide |
Obesity Vasodilator Agents Diuretics Sodium Chloride Symporter Inhibitors Vascular Diseases Calcium Channel Blockers Cardiovascular Agents |
Antihypertensive Agents Hydrochlorothiazide Amlodipine Calcium, Dietary Valsartan Hypertension |
Vasodilator Agents Molecular Mechanisms of Pharmacological Action Diuretics Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Vascular Diseases Calcium Channel Blockers Cardiovascular Agents Antihypertensive Agents |
Hydrochlorothiazide Pharmacologic Actions Amlodipine Membrane Transport Modulators Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Valsartan Hypertension |